Abiopharma

🔍 SPECTOR DAVID (Director)

Company: PennyMac Financial Services, Inc. (PFSI)

Report Date: 2026-04-14

Detailed Transactions and Holdings:

• Sold 9,583 shares of Common Stock at $92.8 per share (Direct)
  Date: 2026-04-14 | Code: S | equity_swap_involved: 0 | shares_owned_after: 71,021.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 417 shares of Common Stock at $93.47 per share (Direct)
  Date: 2026-04-14 | Code: S | equity_swap_involved: 0 | shares_owned_after: 70,604.00 | transaction_form_type: 4 | Footnotes: F1, F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-04-14 | Code: H | shares_owned_after: 529,401.00 | Footnotes: F4

Footnotes:

• F1: The sales reported in the Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025.
• F2: The price reported is the weighted average price of multiple transactions ranging from $92.29 to $93.28. The reporting person hereby undertakes to provide upon request to the SEC, the Issuer or a security holder of the Issuer the number of Common Stock and the prices at which the transactions were effected.
• F3: The price reported is the weighted average price of multiple transactions ranging from $93.36 to $93.735. The reporting person hereby undertakes to provide upon request to the SEC, the Issuer or a security holder of the Issuer the number of Common Stock and the prices at which the transactions were effected.
• F4: The reported amount consists of 37,841 restricted stock units and 491,560 shares of Common Stock. The restricted stock units are to be settled in an equal number of shares of Common Stock upon vesting.